Loading clinical trials...
Loading clinical trials...
Nebulized Furosemide for Pulmonary Inflammation in Intubated Patients With COVID-19 - A Phase 2/3 Study
Conditions
Interventions
Nebulized Furosemide
Nebulized Saline
Locations
4
Canada
University of Alberta
Edmonton, Alberta, Canada
Dalhousie University
Halifax, Nova Scotia, Canada
Kingston Health Sciences Center
Kingston, Ontario, Canada
Hôpital Maisonneuve-Rosemont
Montreal, Quebec, Canada
Start Date
April 16, 2021
Primary Completion Date
February 1, 2023
Completion Date
April 30, 2023
Last Updated
December 11, 2023
NCT06213168
NCT07451977
NCT06189924
NCT07186933
NCT05686850
NCT06286917
Lead Sponsor
Dr. John Muscedere
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions